Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: Findings from the ORTHO-TEP registry

Thrombosis and Haemostasis

Volumn 109, Issue 1, 2013, Pages 154-163

  Beyer Westendorf, Jan ^a   Lützner, Jörg ^a   Donath, Lars ^a   Tittl, Luise ^a   Knoth, Holger ^a   Radke, Oliver C ^a   Kuhlisch, Eberhard ^b   Stange, Thoralf ^b   Hartmann, Albrecht ^a   Günther, Klaus Peter ^a   Weiss, Norbert ^a   Werth, Sebastian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Low molecular weight heparin; Major orthopaedic surgery; Rivaroxaban; Venous thromboembolism; VTE prophylaxis

Indexed keywords

FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

ADULT; AGED; ARTICLE; BLEEDING; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HIP ARTHROPLASTY; HUMAN; LENGTH OF STAY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD TRANSFUSION; FEMALE; FIBRINOLYTIC AGENTS; GERMANY; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MORPHOLINES; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; THIOPHENES; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84872224099     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-07-0510     Document Type: Article

References (26)

1. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20: 1-37.
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 381S-453S.
3. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e278S-325S.
4. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007; 89: 799-807.
5. Wilke T, Moock J, Muller S, et al. Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery. Clin Orthop Relat Res 2010; 468: 2437-2453.
6. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
7. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
8. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
9. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
10. Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453.
11. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005; 365: 82-93.
12. Fortin M, Dionne J, Pinho G, et al. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med 2006; 4: 104-108.
13. Rosser WW. Application of evidence from randomised controlled trials to general practice. Lancet 1999; 353: 661-664.
14. Donath L, Lutzner J, Werth S, et al. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low-molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery-findings from the ORTHO-TEP registry. Br J Clin Pharmacol 2012; epub ahead of print.
15. Beyer-Westendorf J, Lutzner J, Donath L, et al. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopaedic surgery-findings from the ortho-tep registry. J Thromb Haemost 2012; epub ahead of print.
16. Schwarz T, Schmidt B, Schmidt B, et al. Interobserver agreement of complete compression ultrasound for clinically suspected deep vein thrombosis. Clin Appl Thromb Hemost 2002; 8: 45-49.
17. Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 2003; 89: 228-234.
18. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
19. Schellong SM. Distal DVT: worth diagnosing? Yes. J Thromb Haemost 2007; 5 (Suppl 1): 51-54.
20. Righini M, Paris S, Le Gal G, et al. Clinical relevance of distal deep vein thrombosis. Review of literature data. Thromb Haemost 2006; 95: 56-64.
21. Seinturier C, Bosson JL, Colonna M, et al. Site and clinical outcome of deep vein thrombosis of the lower limbs: an epidemiological study. J Thromb Haemost 2005; 3: 1362-1367.
22. Iskander GA, Nelson RS, Morehouse DL, et al. A: Incidence and propagation of infrageniculate deep venous thrombosis in trauma patients. J Trauma 2006; 61: 695-700.
23. Chagnon I, Bounameaux H, Aujesky D, et al. Comparison of Two Clinical Prediction Rules and Implicit Assessment among Patients with Suspected Pulmonary Embolism. Am J Med 2002; 113: 269-275.
24. Schiff RL, Kahn SR, Shrier I, et al. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis. Chest 2005; 128: 3364-3371.
25. Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009; 91: 636-644.
26. Kistler U, Kramers-de Quervain I, Munzinger U, et al. Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery. Thromb Haemost 2008; 99: 1049-1052.